You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華納藥廠(688799.SH):恩替卡韋顆粒、複合磷酸氫鉀注射液新增納入2022年國家醫保目錄
格隆匯 01-18 23:21

格隆匯1月18日丨華納藥廠(688799.SH)公佈,根據國家醫療保障局網站於2023年1月18日發佈的《國家醫保局人力資源社會保障部關於印發<國家基本醫療保險、工傷保險和生育保險藥品目錄(2022年)>的通知》(醫保發〔2023〕5號),公司的產品恩替卡韋顆粒、複合磷酸氫鉀注射液新增納入本次《2022年國家醫保目錄》。

恩替卡韋顆粒是公司研發的一款2.2類改良劑新藥,該產品為全國獨家劑型。國家藥品監督管理局(NMPA)以兒童用藥優先審評批准恩替卡韋顆粒上市,用於治療成人和2歲及以上兒童患者慢性乙型肝炎。

複合磷酸氫鉀注射液是公司從臨牀需求出發研發的一種安全補磷、有效補鉀的補磷藥。該產品在藥品領域中應用較廣泛,主要用於完全胃腸外營養療法中作為磷的補充劑,亦可用於某些疾病所致低磷血癥。

上述兩個品種本次納入《2022年國家醫保目錄》後,預計將對產品未來的銷售起到積極作用。《2022年國家醫保目錄》將於2023年3月1日起正式執行,對公司近期經營業績不會產生重大影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account